Acute myeloid leukemia

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

A Correction to this article was published on 06 March 2020

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

Change history

  • 06 March 2020

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

  1. 1.

    Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

    Article  Google Scholar 

  2. 2.

    Nissan MH, Rosen N, Solit DB. ERK pathway inhibitors: how low should we go? Cancer Discov. 2013;3:719–21.

    CAS  Article  Google Scholar 

  3. 3.

    Baines AT, Xu D, Der CJ. Inhibition of RAS for cancer treatment: the search continues. Future Med Chem. 2011;3:1787–808.

    CAS  Article  Google Scholar 

  4. 4.

    Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol. 2012;158:519–22.

    CAS  Article  Google Scholar 

  5. 5.

    Ward AF, Braun BS, Shannon KM. Targeting oncogenic RAS signaling in hematologic malignancies. Blood. 2012;120:3397–406.

    CAS  Article  Google Scholar 

  6. 6.

    Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, et al. Response and resistance to MEK inhibition in leukemias initiated by hyperactive RAS. Nature. 2009;461:411–4.

    CAS  Article  Google Scholar 

  7. 7.

    Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8:184–95.

    CAS  Article  Google Scholar 

  8. 8.

    Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to B-Raf and MEK inhibitors. Cancer Discov. 2013;3:742–50.

    CAS  Article  Google Scholar 

  9. 9.

    Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Kindler L, et al. Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Abstract 4973; Proc AACR Annual Meeting 2017; 1–5 April 2017, Washington, DC.

  10. 10.

    Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433–43.

    CAS  Article  Google Scholar 

  11. 11.

    Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–41.

    CAS  Article  Google Scholar 

  12. 12.

    Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, et al. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173–83.

    CAS  Article  Google Scholar 

  13. 13.

    Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, et al. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017;8:67639–50.

    Article  Google Scholar 

  14. 14.

    Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007;1773:1299–310.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was funded by Eli Lilly and Company, and the Project Program Grant, NIH PO1CA66996.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Ellen Weisberg or James D. Griffin.

Ethics declarations

Conflict of interest

JDG receives funding and has received a royalty payment from Novartis Pharmaceuticals and receives funding from Eli Lilly and Company. N is a founder, science advisory board member (SAB), and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield, and Sanofi. EW has received a royalty payment from Novartis Pharmaceuticals. RS does Ad Hoc consulting for and receives clinical research support to Dana-Farber Cancer Institute from the following companies: Abbvie, Agios, Arog, and Novartis. He does Ad Hoc consulting for the following companies: Astrazeneca, Cornerstone, Jazz, Daiichi-Sankyo, Otsuka/Astex, Pfizer, and Stemline. He is on the Advisory Board of the following companies: Actinium, Amgen, Astellas, and Macrogenics. He is on the Data Safety and Monitoring Board for the following companies: Argenx, Celgene, and Takeda. He is an Ad Hoc Consultant and on the Steering Committee and Data Safety and Monitoring Board for Celgene. SVB is an employee and shareholder of Eli Lilly and Company. RVT was an employee and is a shareholder of Eli Lilly and Company, and is currently employed by Astellas Pharma.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weisberg, E., Meng, C., Case, A. et al. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 625–629 (2020). https://doi.org/10.1038/s41375-019-0552-3

Download citation

Further reading

Search